银屑病
医学
生物制剂
加药
乌斯特基努马
临床试验
英夫利昔单抗
毒品类别
肿瘤坏死因子α
持久性(不连续性)
重症监护医学
药品
皮肤病科
药理学
内科学
疾病
岩土工程
工程类
作者
Lluís Rusiñol,Elena Carmona‐Rocha,L. Puig
标识
DOI:10.1080/1744666x.2023.2250918
摘要
Significant advances in psoriasis treatment have taken place since the introduction of biologics. Tumor necrosis factor inhibitors were the first class of biologics approved and at that time greatly improved psoriasis treatment. However, newer biologics, directed to interleukin(IL)-23/IL-17 pathways central to psoriasis pathogenesis, have improved complete or nearly complete clearance rates and are characterized by an excellent safety profile.Real-world setting experiences have generally confirmed the results of clinical trials, but real-world data regarding newer biologics is relatively scarce.We provide an extensive review of real-world survival of biologic treatments for moderate to severe psoriasis.There is growing and consistent evidence of higher drug survival of IL-23 inhibitors, possibly due to their favorable efficacy and safety profiles, dosing convenience and persistence of response despite treatment interruption; eventual confirmation of their potential role as modifiers of the natural history of psoriasis might provide additional reasons for therapeutic persistence of this class of biologics.
科研通智能强力驱动
Strongly Powered by AbleSci AI